Flu Vaccine Efficacy Examined in Southern Hemisphere Countries
By Elana Gotkine HealthDay Reporter
MONDAY, Oct. 7, 2024 -- Based on data from Southern Hemisphere countries, a low proportion of patients with influenza-associated severe acute respiratory illness (SARI) were vaccinated against influenza, according to research published in the Oct. 3 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Erica E. Zeno, Ph.D., from the CDC in Atlanta, and colleagues conducted interim estimates of influenza vaccine effectiveness (VE) from Southern Hemisphere countries, which can help guide Northern Hemisphere countries in advance of their season. Interim VE against influenza-associated SARI hospitalization was estimated using data from a multicountry network.
The researchers identified 11,751 influenza-associated SARI cases during March 13 to July 19, 2024, in Argentina, Brazil, Chile, Paraguay, and Uruguay. On average, 21.3 percent of these patients were vaccinated against influenza, with an adjusted VE of 34.5 percent against hospitalization. The adjusted VE was 36.5 percent against the predominating subtype A(H3N2) and was 37.1 percent against A(H1N1)pdm09.
"These data suggest that influenza vaccine demand was still low post-COVID-19 but that vaccination prevented approximately one-third of influenza-associated hospitalizations among groups at high risk for influenza-associated complications," the authors write. "These findings support [the U.S. Centers for Disease Control and Prevention and World Health Organization's] recommendation that all eligible persons aged ≥6 months should receive influenza vaccination."
One author disclosed participating on a data safety monitoring board for Moderna's candidate mRNA respiratory syncytial virus vaccine for pregnant women.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
35 Percent of Eligible Children Receive RSV Prophylaxis With Nirsevimab
TUESDAY, July 22, 2025 -- Despite near universal availability of nirsevimab, only 35 percent of eligible children receive nirsevimab for respiratory syncytial virus (RSV)...
2020 to 2024 Saw Drop in Flu Vaccine Uptake Among U.S. Adults
FRIDAY, July 18, 2025 -- There was an overall decrease in influenza vaccine uptake among U.S. adults from 2020 to 2024, according to a study published online July 16 in PLOS...
No Risks Seen With Early Childhood Exposure to Aluminum-Adsorbed Vaccines
TUESDAY, July 15, 2025 -- Early childhood exposure to aluminum-adsorbed vaccines is not associated with an increased risk for autoimmune, atopic or allergic, or neurodevelopmental...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.